15 registrations that name liraglutide as a study arm and are recruiting or about to, as ClinicalTrials.gov listed them on Oct 20, 2026. Read each listing for its full criteria and current status.
Kymata never assesses eligibility. Each listing names its own criteria; only its study team can say whether someone can join. Trial doses are given under the trial's monitoring and are not a schedule for anyone outside it.
Filter 15 registrations
Status
Phase
6US sites across 5 states
1
2 to 4
5 to 19
20 or more
All 15 registrations
RecruitingNCT04575844
Effects of Exercise and GLP-1 Agonism on Muscle Microvascular Perfusion and Insulin Action in Adults With Metabolic Syndrome
Phase 4
University of Virginia
About 80 people
Started Nov 1, 2020
In plain words A Phase 4 study of liraglutide in people 21 to 60, run by University of Virginia. It plans to enroll about 80 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 21 to 60; healthy volunteers accepted. Conditions: Metabolic Syndrome.
Male or female ≥21 and ≤60 years old.
Body mass index >25 and ≤35 kg/m2 and is weight stable (<5 kg weight change in the past 6 months). BMI is limited to ≤35 kg/m2 for easier vascular access and cardiac imaging.
Meet 3 of 5 National Cholesterol Education Program Adult Treatment Panel III Metabolic Syndrome criteria:
Increased waist circumference (≥102 cm in men; ≥88 cm in women)
12 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Liraglutide; Exercise training; Liraglutide + Exercise training
Registered summary
The primary objective of this study is to examine whether exercise training alone, liraglutide treatment alone or exercise training plus liraglutide treatment increases cardiac and skeletal muscle microvascular blood volume, improves vascular function of the conduit vessels, and enhances insulin's metabolic action in humans with Metabolic Syndrome. Subjects will be randomized to one of the 4 groups: control, exercise training, liraglutide treatment, and exercise + liraglutide. They will be studied at the baseline and then after 24 weeks of intervention.
Where, as registered
1 US site in 1 state.
RecruitingNCT07225816
Examination of How the Duration of Fasting and Temporary Stopping of GLP-1 Medications Affect the Amount of Food Left in the Stomach in People Using Liraglutide (Injected), Semaglutide (Taken by Mouth) or Semaglutide (Injected)
Phase 1
Novo Nordisk A/S
About 71 people
Started Nov 7, 2025
In plain words A Phase 1 study of liraglutide in people 18 and older, run by Novo Nordisk A/S. It plans to enroll about 71 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Obesity.
Male or female.
Age 18 years or above at the time of signing the informed consent.
BMI between 25.0 and 45 kilogram per meter square (kg/m\^2) (both inclusive) at screening. Overweight should be due to excess adipose tissue, as judged by the investigator.
Diagnosed with type 2 diabetes (T2D) more than (>) 180 days before screening.
3 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Liraglutide; Oral Semaglutide; Semaglutide
Registered summary
The purpose of this study is to investigate how the duration of fasting and temporary stopping of Glucagon-Like-Peptide 1 (GLP-1) medications affect the amount of food left in the stomach in people using liraglutide (injected), semaglutide (taken by mouth) or semaglutide (injected). The length of participants participation in the study will depend on the type of GLP-1 RA treatment participants are already using.
Where, as registered
1 US site in 1 state.
RecruitingNCT03883412
Effect of Exercise and/or Liraglutide on Vascular Dysfunction and Insulin Sensitivity in Type 2 Diabetes ( ZQL007)
Phase 4
University of Virginia
About 60 people
Started Feb 28, 2019
In plain words A Phase 4 study of liraglutide in people 21 to 60, run by University of Virginia. It plans to enroll about 60 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 21 to 60; healthy volunteers accepted. Conditions: Type2 Diabetes.
Age 21-60
A1C ≤ 8.5%
Never on GLP-1RA (eg: exenatide, liraglutide) or DPP4I ( eg: Sitaglipton)
On stable dose of oral hypoglycemic agents >4 months
1 more inclusion criterion and the exclusion criteria are on the listing.
What it tests, as registered
Exercise; Liraglutide
Registered summary
The primary objective of this study is to examine whether exercise training alone, liraglutide treatment alone or exercise training plus liraglutide treatment increases cardiac and muscle capillary blood volume, improves vascular function in the larger conduit vessels, and enhances insulin's metabolic action in humans with Type 2 diabetes. Subjects will be randomized to one of the three groups: exercise training, liraglutide treatment, and exercise + liraglutide. They will be studied at the baseline and then after 16 weeks of intervention.
Where, as registered
1 US site in 1 state.
RecruitingNCT06976619
The Effect of Glycemic Control and of GLP-1 Receptor Agonism on Islet GLP-1 in People With Type 1 and Type 2 Diabetes
Phase 2
Mayo Clinic
About 60 people
Started Oct 3, 2025
In plain words A Phase 2 study of liraglutide in people 25 to 70, run by Mayo Clinic. It plans to enroll about 60 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 25 to 70. Conditions: Type 1 Diabetes; Type 2 Diabetes.
Type 1 or type 2 diabetes treated with insulin
The exclusion criteria are on the listing.
What it tests, as registered
Liraglutide Pen Injector; Saline Injections
Registered summary
The investigators recently demonstrated that blockade of Glucagon-Like Peptide-1's (GLP-1) receptor (GLP1R) results in changes in islet function without changes in circulating GLP-1. These effects are more pronounced in people with early type 2 diabetes (T2DM) in keeping with increased expression of PC-1/3 and GLP-1 that is observed in diabetic islets. However, its regulation is at present unknown. There is evidence that α-cell proglucagon processing is subject to paracrine regulation by the β-cell3. The full summary is on the listing.
Where, as registered
1 US site in 1 state.
RecruitingNCT07029009
Liraglutide Treatment in Patients With Maturity-onset Diabetes of the Young (MODY)
Phase 2
Mansa
About 50 people
Started May 8, 2025
In plain words A Phase 2 study of liraglutide in people 10 and older, run by Mansa. It plans to enroll about 50 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 10 and older. Conditions: Maturity Onset Diabetes of the Young.
Diagnosis of MODY via genetic testing
HgbA1c >6.5%
The exclusion criteria are on the listing.
What it tests, as registered
Liraglutide
Registered summary
The reason for this research study is to better understand the use of liraglutide, a commonly prescribed Type 2 diabetes medication, in patients with a diagnosis of maturity-onset diabetes of the young (MODY). The investigators are interested in better understanding the way that this drug affects the metabolism and hormone levels of a person with MODY. Many people with MODY report having gastrointestinal (GI) issues such as an upset stomach. Investigators also are interested in finding out if this drug will help with GI issues. The full summary is on the listing.
Where, as registered
1 US site in 1 state.
RecruitingNCT05681299
Effects of GH and Lirglutide on AgRP
Phase 4
Columbia University
About 40 people
Started May 1, 2023
In plain words A Phase 4 study of liraglutide in people 18 to 45, run by Columbia University. It plans to enroll about 40 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 45; healthy volunteers accepted. Conditions: Healthy; Growth Hormone Deficiency.
40 healthy subjects, 20 male, 20 female, ages 18-45 yr.: (i) 20 (10 male, 10 female) who are overweight/Class 1 Obese (BMI 25-34.9) with abdominal fat accumulation (central adiposity) defined by waist circumference (WC) ≥ 102 cm in men, ≥…
No medical conditions except being overweight/obese in half of subjects
No prescription medication or other drug use
On screening testing: BP<140/<90 mmHg, HbA1c<5.7%, FPG<100 mg/dL, normal IGF-1 and TSH levels.
8 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
growth hormone and lirglutide; growth hormone; liraglutide; Placebo
Registered summary
This is a randomized, placebo-controlled, cross-over study with 4 arms. Healthy and GH deficient adults ages 18-45 years will be studied. Arms will consist of 21-day treatment periods and be separated by 8-week washout periods. Subjects will receive, in random order: i) GH alone, ii) GH with liraglutide, iii) liraglutide alone and iv) placebo. Each phase of the study will consist of a 7-day baseline period including 2 days of testing and 21 days on therapy with visits on days 2, 7, 14 and 21. The full summary is on the listing.
Where, as registered
1 US site in 1 state.
RecruitingNCT06742710
Liraglutide Treatment in Obese Infertile PCOS Women
Phase 4
Peking University Third Hospital
About 890 people
Started May 22, 2025
In plain words A Phase 4 study of liraglutide in female participants 20 to 40, run by Peking University Third Hospital. It plans to enroll about 890 people at 3 sites, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists female participants 20 to 40. Conditions: PCOS; Obesity; Infertility.
Women with polycystic ovary syndrome (PCOS) who meet the Rotterdam diagnostic criteria.
Aged 20-40 years;
25 kg/m2 ≤ BMI ≤ 35 kg/m2;
Have not used any anti-diabetes or weight-loss medications (metformin excluded) within the past 3 months;
2 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Liraglutide and metformin; Metformin
Registered summary
Liraglutide, a hypoglycemic drug, can reduce weight and improve insulin resistance while stabilizing blood glucose metabolism without increasing the risk of hypoglycemia, and has been approved by the State Food and Drug Administration of China and the US Food and Drug Administration for the treatment of obesity. Polycystic ovary syndrome (PCOS) is the main cause of female anovulatory infertility, and it is also a high-risk group of obesity. The full summary is on the listing.
Where, as registered
No US site; China (3).
RecruitingNCT07244003
Efficacy and Safety of the Met+SGLT-2i+GLP-1RA in Patients With Type 2 Diabetes With Poor Glycemic Control
In plain words A Phase 4 study of liraglutide in people 18 to 75, run by Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.. It plans to enroll about 430 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 75. Conditions: T2DM (Type 2 Diabetes Mellitus).
Meet the diagnostic criteria for type 2 diabetes (refer to the Chinese Guidelines for the Prevention and Treatment of Type 2 Diabetes (2020 edition)); -Age: 18-75 years old (including the threshold), male or female;
Body mass index (BMI) ≥20kg/m² ;
Patients who took 1000mg or more of metformin in combination with or without another oral hypoglycemic agent (except SGLT-2i and oral GLP-1RA) for at least 8 weeks before screening and had poor blood glucose control (centralized detection…
Volunteer to participate in this study and sign informed consent.
The exclusion criteria are on the listing.
What it tests, as registered
Metformin; Triple Therapy of Other Oral Antidiabetic Drugs; ganagliflozin; liraglutide
Registered summary
The main objective of this study is to compare the efficacy and safety of the triple combination therapy of Met/SGLT-2i/GLP-1RA or other oral antidiabetic drugs in patients with type 2 diabetes exhibiting poor glycemic control.
Where, as registered
No US site; China (1).
RecruitingNCT06361238
Liraglutide in Preventing Delirium in Diabetic Elderly After Cardiac Surgery
Phase 3
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
About 260 people
Started Nov 19, 2024
In plain words A Phase 3 study of liraglutide in people 60 and older, run by The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School. It plans to enroll about 260 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 60 and older. Conditions: Delirium, Postoperative.
Age ≥ 60 years
Type 2 diabetes
Patients undergoing elective cardiac surgery
The exclusion criteria are on the listing.
What it tests, as registered
Liraglutide injection; Placebo injection
Registered summary
This study aims to clarify the preventive effect of perioperative liraglutide application on postoperative delirium in elderly patients with Type 2 diabetes undergoing cardiac surgery.
Where, as registered
No US site; China (1).
RecruitingNCT07309094
Clinical, Morphometric and Biochemical Effects on Adiposopathy Associated With the Use of GLP-1RA in CKD
Observational
Cardenal Herrera University
About 250 people
Started Sep 15, 2023
In plain words An observational study of liraglutide in people 18 to 90, run by Cardenal Herrera University. It plans to enroll about 250 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 90. Conditions: Chronic Kidney Disease stage3; Chronic Kidney Disease stage4; Chronic Kidney Disease Stage 1; Chronic Kidney Disease Stage 2; Obesity; Diabetes Mellitus, Type 2.
> or = 18 years of age
diagnosed with CKD in stages G1, G2, G3a, G3b, and G4, not candidate for dialysis
had uncontrolled T2DM, CVDs and/or obesity
willing to participate in the study and sign informed consent
The exclusion criteria are on the listing.
What it tests, as registered
GLP-1 receptor agonist; SGLT2 inhibitor; Tirzepatide; Other drugs
Registered summary
Chronic kidney disease (CKD) is the progressive damage to kidney function, associated with an increased risk of cardiovascular diseases, such as stroke or myocardial infarct, particularly in the most severe stages of CKD, in which the patient requires dialysis. Several risk factors are reported for CKD, such as diabetes mellitus, obesity and hypertension. One of the most increasingly recognized risk factors is the fat tissue malfunction, known as adiposopathy. The full summary is on the listing.
Where, as registered
No US site; Spain (1).
RecruitingNCT03087032
Liraglutide-bolus vs Glargine-bolus Therapy in Overweight/Obese Type 2 Diabetes Patients (LiraGooD)
Phase 4
The First Affiliated Hospital of Xiamen University
About 164 people
Started Jan 10, 2019
In plain words A Phase 4 study of liraglutide in people 18 to 75, run by The First Affiliated Hospital of Xiamen University. It plans to enroll about 164 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 75. Conditions: Type 2 Diabetes Patients; Overweight and Obesity; Hyperglycaemia (Diabetic).
Age: 18 - 75 years old.
BMI must be greater than 24 and less than 45 kg/m2
Patients with type 2 diabetes who met the World Health Organization (who) diagnostic criteria (1999).
Newly diagnosed type 2 diabetic patients with HbA1c ≥ 9.0%；or patients with uncontrolled type 2 diabetes (HbA1c ≥ 7.5% ) who have received at least two types of oral hypoglycemic drugs (the dose of each drug needs to reach the second…
1 more inclusion criterion and the exclusion criteria are on the listing.
What it tests, as registered
Liraglutide; insulin glargine
Registered summary
The present 24-week, prospective, open-label, randomized, multicenter, parallel group trial is carried to investigate and evaluate the efficacy and safety of Liraglutide in combination with prandial insulin therapy vs insulin glargine in combination with prandial insulin therapy in overweight / obese patients with uncontrolled type 2 diabetes.
Where, as registered
No US site; China (1).
RecruitingNCT06836284
The Evira Study: Additional Support During Obesity Treatment
No phase
Karolinska Institutet
About 40 people
Started Feb 13, 2026
In plain words A study of liraglutide in people 12 to 17, run by Karolinska Institutet. It plans to enroll about 40 people at 3 sites, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 12 to 17. Conditions: Childhood Obesity; Treatment Adherence.
Patients offered liraglutide or semaglutide in accordance with the clinic's routines.
Aged 12-17 years at the time of inclusion.
The family agrees to participate in a clinical study.
The exclusion criteria are on the listing.
What it tests, as registered
Digi-physical treatment tool, Evira; Obesity medication with liraglutide or semaglutide
Registered summary
The goal of this clinical trial is to evaluate the effect of adding a digi-physical treatment tool as a complement to the local treatment with obesity medication in adolescents with obesity. The main question it aims to answer is: \- Can a combination of a digi-physical treatment tool and obesity medication improve treatment outcomes for patients with obesity compared to patients treated with obesity medications alone? This is a randomized controlled two-arm multicenter study where participants will be randomized to the intervention group (digi-physical treatment+medication) or control group… The full summary is on the listing.
Where, as registered
No US site; Sweden (3).
RecruitingNCT05268237
Safety, Tolerability and Preliminary Efficacy of Sublingual Liraglutide in Patients With Type 2 Diabetes Mellitus
Phase 1 and 2
Biolingus
About 15 people
Started Apr 25, 2023
In plain words A Phase 1 and 2 study of liraglutide in people 18 to 65, run by Biolingus. It plans to enroll about 15 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 65. Conditions: Diabete Type 2.
Males and females aged 18-65 years (inclusive)
Body mass index (BMI) 18-35 kg/m2, inclusive
Normal blood pressure or well managed hypertension (systolic blood pressure <160mmHg, diastolic blood pressure <100 mmHg)
Confirmed diagnosis of T2DM (by repeated laboratory findings) for at least 1 year.
15 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Liraglutide; Placebo
Registered summary
This is a phase Ib/IIa, single ascending dose study of the safety, tolerability and preliminary efficacy of sublingual (SL) Liraglutide in patients with type 2 diabetes mellitus (T2DM).
Where, as registered
No US site; Hong Kong (1).
Not yet recruitingNCT07301437
RWS of of Liraglutide Alone and in Combination With Orlistat for Weight Loss in Overweight/Obese Patients.
Phase 4
The Fourth Affiliated Hospital of Zhejiang University School of Medicine
About 120 people
Starts May 1, 2026 (estimated)
In plain words A Phase 4 study of liraglutide in people 18 to 65, run by The Fourth Affiliated Hospital of Zhejiang University School of Medicine. It plans to enroll about 120 people and lists no sites yet.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 65. Conditions: Overweight and Obese Adults.
BMI: ≤ 35 kg/m² and ≥ 30 kg/m², or ≥ 27 kg/m² and having at least one obesity-related complication (such as hypertension, type 2 diabetes, dyslipidemia)
Voluntarily sign the informed consent form, agreeing to cooperate in completing the 24-week treatment and follow-up.
No severe cognitive impairment or mental illness, and able to understand and comply with the research requirements.
The exclusion criteria are on the listing.
What it tests, as registered
liraglutide monotherapy; liraglutide combined with orlistat
Registered summary
To evaluate the differences in weight loss between liraglutide monotherapy and combined with orlistat in overweight/obese patients.
Where, as registered
No sites listed yet.
Not yet recruitingNCT06865365
Preoperative Use of Liraglutide Additionally to Common Dietological Measures as Opposed to Dietological Measures Alone
Phase 4
Medical University of Vienna
About 72 people
Starts May 1, 2025 (estimated)
In plain words A Phase 4 study of liraglutide in people 18 and older, run by Medical University of Vienna. It plans to enroll about 72 people and lists no sites yet.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Obesity, Adolescent.
BMI > 35.0 kg/m2
Health insurance via Österreichische Gesundheitskasse
Willingness to be assigned to either of the two groups
Willingness to adhere to preoperative dietological measures
2 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Liraglutide daily (0.6-3.0mg, highest tolerable dose) additional to dietological measures and lifestyle optimization suggestions; Dietologic measures and lifestyle optimization for weight loss
Registered summary
The aim of the study is to investigate the effects of preoperative Saxenda (liraglutide). There are two groups, one group receives Saxena in addition to dietary measures when first seeking the operation, one group only diet. The investigator is researching how much additional preoperative weight loss is possible with the drug admitted preoperatively.